Long-term metformin treatment was associated with fewer cardiovascular events than glipizide therapy in type 2 diabetes patients with a history of coronary artery disease, according to a study in Diabetes Care. Data on 304 patients showed 35.1% of glipizide-treated patients experienced cardiovascular events at five years, compared with 25% of metformin-treated patients.
Metformin outperforms glipizide in preventing CVD events in diabetes
SmartBrief Job Listings for Health Care
|Health Economics & Reimbursement Manager - Transcatheter Heart Valve||
|Sr. Medical Device Reimbursement Specialist - Regional||
|Fort Worth , TX|
|Assistant General Counsel/Senior Corporate Counsel - Healthcare Law Group||
|Clinical Trials Agreements Specialist (209955)||
The Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
|SAFETY, HEALTH, and ENVIRONMENTAL (SHE) REGIONAL SPECIALIST||
Matheson Tri-Gas, Inc.